Efficacy observation of Aripiprazole and Risperidone in treatment of schizophrenia

Objective: To investigate efficacy and safety of Aripiprazole and Risperidone in treatment of schizophrenia. Methods: 76 cases of schizophrenia in line with CCMD3 were randomly divided into two groups,38 cases in each group. They were given Aripiprazole and Risperidone for 6 weeks. The adverse reactions and clinical efficacy of the two groups were assessed. Results: The total effective rate of Aripiprazole group was 89. 47%,which was similar to that of Risperidone group( 86. 84%)( P 0. 05). There was a statistical difference in the PANSS score between the two group before and after the treatment( P 0. 05); however,there were no statistical differences in the PANSS score between the two group at each time point( P 0. 05). Six weeks after the treatment,the incidence rates of adverse reactions of Aripiprazole group were lower than those of Risperidone group( P 0. 05). Conclusions: In the treatment of schizophrenia,Aripiprazole has a similar efficacy with Risperidone,but is superior in influences on extrapyramidal reactions,endocrine and weight than Risperidone.